Antiseizure Medications in Pregnancy Linked to Fetal Growth Risks
Personalized briefing
Discovery of the day · Neurology
Antiseizure medication use in pregnancy and the risk of poor fetal growth in the EURAP international registry: a prospective cohort study
Dear Kelly M Leyden, this is your personalized scientific intelligence briefing — curated for your work in Neurology.
Key finding
Medicine · Neurology
Discovery of the day
Poor fetal growth must now be recognized as an important adverse outcome of prenatal antiseizure medication exposure, in addition to the well-documented congenital malformations and neurodevelopmental effects. Using prospective data from the large EURAP international registry, researchers demonstrated that risk varies significantly across individual antiseizure monotherapies and specific combinations, and escalates with the number of concomitant medications. For clinicians managing women with epilepsy, this evidence strengthens the case for individualized risk prediction and treatment selection during preconception counseling, underscoring the need for multimodal biomarkers that integrate clinical history with objective measures to guide safer therapeutic decisions.
Novelty
90%
Rigor
94%
Significance
78%
Validity
92%
Clarity
88%
Advertisement
GroupRFQ — join group deals on lab & medical equipment. Pool orders, unlock volume pricing. See open deals →
Your briefing is personalized based on your selected fields, keywords, and research interests.
